Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) has shared an announcement.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 285,122 ordinary shares as part of its $300 million share buyback program announced in August 2025. The shares were bought at prices ranging from 247.00 to 249.00 pence and will be held in treasury. This move is part of ConvaTec’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing its market position and investor confidence.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £2.82 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score reflects its strong financial performance, which is the most significant factor. The company’s robust revenue growth, profitability, and cash flow management are key strengths. However, technical analysis indicates mixed signals, and the valuation suggests the stock may be overvalued, which could limit future gains. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing advanced wound care, ostomy care, continence and critical care, and infusion care products. The company is committed to improving the lives of people with chronic conditions and is a key player in the healthcare market.
Average Trading Volume: 7,619,274
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.96B
For an in-depth examination of CTEC stock, go to TipRanks’ Overview page.